Related Experiment Video
Updated: May 8, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Cd16-Cd56bright NK Cells: A Protective NK Cell Subset for Progression and Prognosis in Amyotrophic Lateral Sclerosis
Zhenxiang Gong1,2, Li Ba1,2, Zehui Li1,2
1department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Abstract:
Amyotrophic lateral sclerosis (ALS) is a non-neuron-autonomous disease where peripheral immune dysregulation significantly impacts disease progression. However, the immunopathological mechanisms of natural killer (NK) cells in ALS remain largely unexplored. This study enrolled 241 ALS patients and 102 healthy controls (HC), analyzing lymphocyte subsets, including T cells, B cells, and NK cells. A sub-cohort of 81 ALS patients was followed up for one year at three-month intervals. Linear mixed and Cox proportional hazards models were used to evaluate the association between lymphocyte subsets and ALS progression and prognosis. Our results revealed significant reductions in total T cells, helper T cells (Th), and NK cells in ALS patients compared to HC (P < 0.05). Slow-progressing ALS patients exhibited higher counts of total T cells, Th, Cd16-Cd56bright NK cells, and Cd16+Cd56bright NK cells, while showing lower counts of Cd16+Cd56dim NK cells compared to fast-progressing ALS patients (P < 0.05). ALS patients with lower Cd16-Cd56bright NK cell counts experienced a faster decline in motor function than those with higher counts (P < 0.05). Elevated Cd16-Cd56bright NK cell counts were associated with improved ALS prognosis (HR, 0.73; 95% CI: 0.60-0.90; P < 0.05). This study suggests that Cd16-Cd56bright NK cells play a protective role in ALS progression and prognosis, offering a potential therapeutic target for ALS.

